CHKA and skin reaction: The meta-analysis showed no statistically significant differences between the two groups in terms of fever (OR = 0.57, 95% CI: 0.30–1.09, P = 0.09), gastrointestinal adverse reactions (OR = 1.36, 95% CI: 0.90–2.06, P = 0.15), and skin reactions (OR = 1.16, 95% CI: 0.35–3.86, P = 0.81), confirming that CKI has a favorable safety profile with no obvious adverse reactions.